8 completed, 7 unknown, 5 recruiting, 1 active not recruiting. 13 Phase 2, 4 Not applicable, 4 Phase 1, 4 Phase 3, 2 Early Phase 1.
Follow Advanced Gastric Adenocarcinoma: new trials by email Literature Review of Advanced Gastric Adenocarcinoma trials Research Report on Advanced Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer EB-DT-CAR-NK, Fludarabine, Cyclophosphamide - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-24 |
| Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma Ivonescimab, FOLFOX regimen, Irinotecan - Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 88 | 2025-11-20 | 2026-04-28 |
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-21 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab camrelizumab - Advanced Gastric Adenocarcinoma | Not applicable | Unknown | Henan Cancer Hospital | 62 | 2022-03-31 | 2022-10-17 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Lenvatinib, Pembrolizumab - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2022-02-14 | 2026-07-16 |
| A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma LY011 - Advanced Gastric Adenocarcinoma | Early Phase 1 | Unknown | Shanghai Longyao Biotechnology Inc., Ltd. | 18 | 2021-11-01 | 2021-07-26 |
| First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC Apatinib Combined With Tislelizumab and Chemotherapy - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Renmin Hospital of Wuhan University | 33 | 2021-03-01 | 2024-02-02 |
| Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer Camrelizumab, Albumin-bound paclitaxel, S-1 - Advanced Gastric Adenocarcinoma | Not applicable | Unknown | Henan Cancer Hospital | 46 | 2020-08-17 | 2022-04-15 |
| Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma Paclitaxel, Olaparib, Pembrolizumab - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 19 | 2020-07-31 | 2026-09-01 |
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer Camrelizumab, Apatinib Mesylate, POF - Advanced Gastric Adenocarcinoma | Not applicable | Unknown | Fujian Cancer Hospital | 20 | 2019-12-10 | 2019-11-22 |
| Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy EV-array - Advanced Gastric Adenocarcinoma, Immunotherapy | Unknown | Shen Lin | 40 | 2018-11-01 | 2021-08-06 | |
| Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment AZD6094, Docetaxel - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 2 | 2017-07-10 | 2019-12-30 |
| Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma CAR-CLD18 T Cells - Advanced Gastric Adenocarcinoma, Pancreatic Adenocarcinoma | Not applicable | Unknown | Changhai Hospital | 24 | 2017-04-01 | 2018-03-12 |
| Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment Volitinib - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 16 | 2016-02-10 | 2022-06-15 |
| PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma GSK2636771, Paclitaxel - Advanced Gastric Adenocarcinoma | Phase 1 / Phase 2 | Completed | Yonsei University | 42 | 2016-02-01 | 2025-01-24 |
| Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors ibrutinib, everolimus, paclitaxel - Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 263 | 2015-12-01 | 2023-11-18 |
| Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment AZD6094, docetaxel - Advanced Gastric Adenocarcinoma | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 7 | 2015-04-30 | 2022-06-15 |
| Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy AZD5363, paclitaxel, AZD2014 - Advanced Gastric Adenocarcinoma | Phase 2 | Terminated | Samsung Medical Center | 27 | 2015-02-12 | 2019-05-20 |
Showing 20 of 22. Sign in to see all of them.
Adenocarcinoma Of Esophagus (3) · Stomach Neoplasms (3) · Adenocarcinoma (2) · Neoplasms (2) · Carcinoma, Renal Cell (1) · Gastrointestinal Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (4) · Neoplasms by Site (4) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Stomach Diseases (3) · Gastrointestinal Neoplasms (2) · Adenocarcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Kidney Neoplasms (1)
Paclitaxel (7) · Docetaxel (4) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (3) · Fluorouracil (3) · Leucovorin (3) · Oxaliplatin (3) · camrelizumab (3) · pembrolizumab (3) · Irinotecan (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Albumin-Bound Paclitaxel (1) · Cetuximab (1) · Cyclophosphamide (1) · Drug Therapy (1)
Samsung Medical Center (5) · Henan Cancer Hospital (2) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Alliance for Clinical Trials in Oncology (1) · Beijing Biotech (1) · Changhai Hospital (1) · Fujian Cancer Hospital (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Pharmacyclics LLC. (1) · Renmin Hospital of Wuhan University (1) · Shanghai Longyao Biotechnology Inc., Ltd. (1) · Shen Lin (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · UNICANCER (1)
China (9) · South Korea (7) · United States (5) · France (1) · Lithuania (1) · Puerto Rico (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Anwaar Saeed (1) · Katherine Bever, MD (1) · Mariela Blum (1) · Mykyta Pepenin, MD (1) · Sun Young Rha (1) · Xianbao Zhan, M.D. (1) · Yuan Chen (1)
PMID 37919668, PMID 40155326, PMID 41550955, PMID 42669571
2015 (1), 2025 (1), U10CA180888 (1)